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1. Introduction 
The use of hyperosmotic agents in stroke is still a matter of debate, since their usefulness has 
repeatedely been suggested but not conclusively demonstrated (Righetti E et al., 2002). 
Better understanding of the possible mechanism of protection by hyperosmotic agents may 
help identifying clinical situations where they may be more useful. It is generally assumed 
that their effect in stroke is due to their capacity to reduce brain edema. However, increasing 
extracellular osmolarity has direct effects on neuronal electrical function (Osehobo and 
Andrew, 1993; Rudehill et al., 1993), and one of us has previously reported that adding 
mannitol to the perfusing medium of brain slices delays anoxic depolarization (AD) 
(Balestrino, 1995a; Balestrino, 1995b). Since the latter is a factor in causing neuronal damage 
in anoxia and ischemia (Balestrino and Somjen, 1986; Jarvis et al., 2001; Kaminogo et al., 
1998; Somjen et al., 1990), this may be another mechanism of brain protection by 
hyperosmotic agents in stroke. This study investigates whether or not this delay occurs at 
values of hyperosmolarity that may be obtained in clinical practice. We first carried out a 
survey of the literature on osmolarity changes after administration of hyperosmotic agents 
in vivo, under both clinical and experimental conditions. Then, we did a dose-response 
study of mannitol-induced delay of AD. Finally we compared the two sets of data to gauge 
whether or not mannitol-induced delay of AD occurs in the range of hyperosmolarity that 
might be obtained in clinical practice. 
2. Materials and methods 
Sprague-Dawley female rats (155-190g.) were anaesthetised with ether and decapitated. The 
left hippocampus was dissected free and cut in 600 µm thick transversal slices. Slices were 
immediately transferred into an "interface" recording chamber (Fine Science Tools, 
Vancouver B. C. Canada) and incubated at 35±1°C. They were bathed by Artificial 
CerebroSpinal Fluid (ACSF) flowing at 2 ml/min and having the following composition: 
NaCl 130 mM, KCl 3.5 mM, NaH2PO4 1.25 mM, NaHCO3 24 mM, CaCl2 2.4 mM, MgSO4 1.2 
mM, glucose 10 mM. This medium was continuously bubbled with 95% O2 / 5% CO2, 
resulting in a pH of 7.35-7.40. The same warmed, humidified 95% O2 / 5% CO2 mixture 
aerated the slices representing the gas phase. Anoxia was induced by replacing oxygen with 
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nitrogen in the gas phase. The DC-coupled, ground-referenced extracellular potential of the 
tissue was constantly monitored in the cell body layer of CA1. As soon as the sudden fall in 
this potential that is the hallmark of AD was observed, oxygen flow was restored. A cross-
over study design was observed, with the same slice being subjected to anoxia, at 30’ 
intervals, both in the presence and in the absence of mannitol. Each slice was subjected to 
two anoxic episodes. The sequence of treatments (mannitol first, or control ACSF first) was 
alternated in consecutive experiments, to minimize the bias due to possible effects of 
repeated anoxia per se on AD latency. In two experiments, the same slice was subjected to 
three anoxic episodes the first one in mannitol, the second in control ACSF, the third one in 
mannitol again. For statistical analysis, in each experiment the difference in latency between 
AD in mannitol and AD in control ACSF was computed, and used as a gauge of mannitol 
efficacy in that experiment.  
3. Results  
3.1 Literature search on serum osmolarity changes in vivo 
Results are summarized in figure 1 and in Table 1.  
 
 
Fig. 1. Increases in serum osmolarity reported in the literature: This figure depicts the 
highest increase in serum osmolarity reported in each of the papers listed in Table 1. It refers 
to papers quoted in the Reference List. This figure is meant to graphically visualize the 
highest reported increases. Refer to Table I and to text for further information. 
In human patients, use of mannitol at the dose of 0.5-2 g/Kg body weight is reported (Cloyd et 
al., 1986; Newman, 1979; Rudehill et al., 1993). Such a dose leads, still in human patients, to a 
maximum increase in serum osmolarity of about 10-32 mOsm (Cloyd et al., 1986; Manninen et 
al., 1987; Rudehill et al., 1993). When experimental animals are considered, administration of  
1 g/Kg body weight to rats yelded a serum osmolarity increase of 4 mOsm (Thenuwara et al., 
2002). In dogs, mannitol administration of 0.5, 1 or 1.5 g/Kg lead to a peak increase (mean±SD) 
of 43±18, 66±18 and 52±23 mOsm, respectively, during the brief time of the infusion, and to the  
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Paper 
Animal 
species 
Osmotic agent 
infused 
Dose 
Serum osmolarity 
increase 
(Cloyd et al., 1986) Humans Mannitol 0.5, 0.7 g/Kg 10 - 18 mOsm  
(Cloyd et al., 1986) Dog Mannitol 0.5, 1, 1.5 g/Kg 43-66 mOsm 
(Jansson and  
Rask-Anderson, 1993) 
Mice Glycerol  
1.3, 2.6 and  
5.2 g /kg  
12-119 mOsm 
(Manninen et al., 1987) Humans Mannitol 1, 2 g/Kg 32 mOsm 
(Newman, 1979) Humans Mannitol 2 g/Kg Not reported 
(Noi and Makimoto, 1998) Guinea pig Glycerol 
30-min infusion 
of 50% glycerol 
6 mOsm 
(Noi and Makimoto, 1998) Guinea pig Urographin® 
30-min infusion 
of 76% 
Urographin® 
25 mOsm  
(Ostensen et al., 1987) Dog Mannitol  40 mOsm 
(Rudehill et al., 1993) Humans Mannitol 1 g/Kg 12 mOsm. 
(Thenuwara et al., 2002) Rat Mannitol 
1, 4, 8 g/Kg, 
with or without 
furosemide 
4-67 mOsm 
Table 1. Literature data on changes in serum osmolarity after i.v. infusion of osmotic 
agents. The table summarizes available literature data on changes in serum osmolarity after 
i.v. infusion of osmotic agents. When different changes in osmolarity are reported following 
different doses of osmotic agent, in the table the range of increases is given. The values 
given in the table are either the numbers provided by the Authors or those obtained by 
measuring graphs in their papers. In the latter case, the value is obviously less precise. 
When the Authors reported mean±SD for pre- and post-infusion osmolarity, in the table the 
corresponding difference between means is given. 
lower increase of 10 mOsm or less afterwards (Rudehill et al., 1993). Higher doses of 
mannitol (4 g/Kg and 8 g/Kg, with or without the addition of furosemide) lead, in rats, to 
a rather high serum osmolarity increase, reaching an average as high as 67 mOsm 
(Thenuwara et al., 2002). Under experimental conditions in vivo, glycerol infusion leads to 
average increases in serum osmolarity of 6 mOsm in guinea pigs (Noi and Makimoto, 
1998) and of up to 119 mOsm in dogs (Jansson and Rask-Anderson, 1993). Using 
Urografin® infusion, a 25 mOsm increase in serum osmolarity was obtained in guinea 
pigs (Noi and Makimoto, 1998).  
3.2 Effects of increasing mannitol in vitro 
The previously shown robust effect of mannitol in delaying AD was first confirmed in 
double wash-out experiments, where the same slice was subjected to transient anoxia in the 
presence of mannitol, then in control ACSF, then again in the presence of mannitol. These 
experiments are illustrated in figure 2. Mannitol concentrations of 100 and 500 mM were 
used in these experiments, as they were those that had been previously shown to most 
reliably delay AD (Balestrino, 1995). 
The effects of mannitol where then investigated at different concentrations. Fig. 3 
summarizes these results. As it can be seen, 1 and 10 mM were not effective in delaying AD. 
Twenty-five mM significantly delayed AD, while 50 mM did not show a statistically 
www.intechopen.com
 
Advances in the Preclinical Study of Ischemic Stroke 
 
402 
significant effect. The quite high concentrations of 100 and 500 mM significantly increased 
the latency of AD. 
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Fig. 2. Double wash-out experiments showing mannitol effectiveness in delaying anoxic 
depolarization. In two different slices, anoxia was induced in mannitol-fortified Artificial 
CerebroSpinal Fluid (ACSF), then in control ACSF, then again in ACSF with added 
mannitol. In one experiment (set of bars at left) 100 mM mannitol were used, in the other 
(set of bars at right) 500 mM mannitol were used. Bars represent latency of AD in each 
anoxia episode. Control ACSF reversibly decreased AD latency, thus confirming the 
previously published efficacy of mannitol in increasing AD latency.  
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Fig. 3. Effects of different mannitol concentrations in delaying anoxic depolarization. The 
bars show latency of AD (mean± SD)in both control and mannitol-fortified ACSF for 
different mannitol concentrations. Asterisks mark the groups in which the difference is 
statistically significant (p<0.03, t-test for paired data). N=3 for 1mM, N=4 for 10 mM, N=8 
for 25 mM, N=7 for 50 mM, N=6 for 100 mM, N=6 for 500 mM. See text for experiment 
design. 
Figure 4 shows an example of AD delay by mannitol. 
In a further analysis, we calculated for each slice the difference between the latency of AD 
in mannitol and the latency of AD in control ACSF. Such a difference was used as a gauge 
of mannitol effectiveness in that particular slice. If the difference had been positive, it 
would have indicated that latency in mannitol was longer that in control (i.e., AD 
occurred later), thus showing protection by mannitol and quantifying its degree. The 
opposite would have been true for a negative difference. Results are shown in Figure 5. 
As it can be seen, above 10 mM all concentrations of mannitol delay AD to a comparable 
extent. Such a finding has already been reported, from our laboratory, for AD delay by 
creatine (Balestrino, 1995).  
www.intechopen.com
 
Advances in the Preclinical Study of Ischemic Stroke 
 
404 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4. Sample anoxic depolarization in control and mannitol-treated ACSF. Two different 
anoxic episodes in the same slice. The dotted line represents DC tracing (showing anoxic 
depolarization) during anoxia in control ACSF, the solid line represents the same tracing 
during anoxia in ACSF with added mannitol. AD occurs later in mannitol-fortified ACSF. 
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Fig. 5. Measure of AD delay in different mannitol concentrations. Same experiments as in 
figure 3. This figure depicts more precisely the increase in AD latency determined by 
mannitol at each concentration. For each slice, the difference (AD latency in ACSF with 
mannitol) – (AD latency in control ACSF) was computed. A positive difference means that 
AD latency was longer in mannitol (i.e., AD occurred later), the opposite is true for a 
negative difference. Data were grouped for mannitol concentration. For each concentration, 
mean±SD is provided. Number of experiments as in figure 3. Concentrations of 25 mM 
mannitol and higher all delay AD to the same extent.  
4. Discussion 
The effectiveness of hyperosmolarity in delaying AD was confirmed by these findings. 
Delay of AD may be relevant to neuroprotection in stroke, because AD is a factor in the 
generation of anoxic damage, and its delay has been associated with better outcome 
under experimental conditions (Balestrino and Somjen, 1986; Jarvis et al., 2001; 
Kaminogo et al., 1998; Somjen et al., 1990). The present study indicates that significant 
delay of AD is obtained at mannitol concentrations greater than 10 mM, 25 mM being the 
lowest effective dose among those tested. An overview of the literature showed that in 
human patients serum osmolarity increases, under common clinical settings, by 10-32 
mOsm after administration of 1 g/Kg mannitol (Table 1 and fig. 1). This is equivalent to 
adding 10-32 mM mannitol to in vitro†slices1. At the lower end of this range, such an 
                                                 
1 Since the molecule of mannitol does not split in acqueous solutions, the molarity of mannitol in 
solution (here expressed in mM) corresponds to the consequent increase in osmolarity (1mM=1mOsm).  
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increase would be insufficient (10 mM (Cloyd et al., 1986; Rudehill et al., 1993) ) or 
perhaps barely sufficient (18 mM (Cloyd et al., 1986)) to afford delay of AD. In the upper 
end, a 32 mM increase (Manninen et al., 1987) would probably be somehow effective in 
delaying AD. In fact, we showed that in vitro the addition of 25 mM mannitol (increasing 
osmolarity by 25 mOsm) significantly delays AD. The delay in AD was not significant 
after addition of 50 mM (increasing osmolarity by 50 mOsm), indicating that these 
osmolarity increases (25-50 mOsm) are of borderline efficacy. However, much higher 
increases, up to 100 mOsm and more, were reliably effective in vitro, and have been 
reported under experimental conditions in laboratory animals, apparently without 
severe adverse effects (Table 1 and figure 1). The latter increases would be in a range that 
does cause AD delay (compare figure 5 with figure 1). If further studies suggested that a 
comparable increase in serum osmolarity can be safely obtained in human patients, it 
might be useful not only by decreasing brain edema, but also by having a direct effect on 
tissue depolarization. 
Two more considerations are in order. 
First, in human stroke mannitol or other hyperosmotic agents would be adiminstered 
when AD has already occurred. In fact, AD is an event that occurs in the core of an 
infarction soon after ischemia. Nevertheless, under experimental conditions continuous or 
repeated depolarizations have been demonstrated in the hours following stroke (Chen et 
al., 1993; Ohta et al., 1997). Their reduction has been associated with better outcome (Chen 
et al., 1993). Given the striking similarity of these events with “classical” AD, it is very 
likely that hyperosmolarity can delay or suppress these waveforms as well, thus 
providing protection. 
Second, the changes reported in the literature are in serum, not in the interstitial space of the 
brain. To the best of our knowledge, no study has yet measured increases in osmolarity in 
the interstitial space of the brain, probably due to the technical difficulty of this 
investigation. However, it is reasonable to assume that an increase in osmotic pressure in 
the serum draws water from the brain interstitial space, thus increasing its osmolarity to a 
comparable degree. Therefore, increase in serum osmolarity should be comparable, at least 
to an extent, to increase in osmolarity of the brain interstitial space. 
Finally, it should be noted that future clinical studies on hyperosmotic agents in stroke 
should take into account the increase in serum osmolarity that was obtained in the single 
patients. In fact, our data indicate that the latter is a critical variable in determining whether 
the hyperosmotic therapy will be effective or not.  
Summing up, we conclude that the increase in serum osmolarity that is commonly obtained 
in clinical practice is not sufficient to delay AD. Larger increases in serum osmolarity have 
been, however, reported in animal experiments. If further studies indicated that such 
increases were safe in humans as well as in animals, they might provide brain protection by 
decreasing AD and AD-like depolarizations. Future clinical studies on hyperosmotic agents 
in stroke should measure and take into account the degree of changes that were obtained in 
serum osmolarity. 
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